Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
Sleep Medicine · 2023
DOI: 10.1016/j.sleep.2023.05.023 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Sleep Medicine, 2023. Verfasst von Charles J Bae und 7 weiteren Autor:innen. Beteiligte Einrichtung: Penn Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Narcolepsy, Sodium Oxybate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: School of Public Health, University of California Berkeley, Jazz Pharmaceuticals plc.
Abstract (Originalsprache)
OBJECTIVES: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). METHODS: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (±7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). RESULTS: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (≤10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). CONCLUSIONS: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Penn Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
- Jazz Pharmaceuticals, Palo Alto, CA, USA.
- Jazz Pharmaceuticals, Philadelphia, PA, USA.
- Jazz Pharmaceuticals, Philadelphia, PA, USA. Electronic address: Wayne.Macfadden@jazzpharma.com.
- Duke University Medical Center, Durham, NC, USA.
Förderung
- School of Public Health, University of California Berkeley
- Jazz Pharmaceuticals plc
Zitieren
APA
Bae, C. J., Zee, P. C., Leary, E. B., Fuller, D. S., Macfadden, W., Candler, S., Steininger, T. L., & Husain, A. M. (2023). Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study. Sleep Medicine. https://doi.org/10.1016/j.sleep.2023.05.023
Vancouver
Bae CJ, Zee PC, Leary EB, Fuller DS, Macfadden W, Candler S, et al. Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study. Sleep Medicine. 2023. doi:10.1016/j.sleep.2023.05.023
BibTeX
@article{Bae2023,
author = {Bae, Charles J and Zee, Phyllis C and Leary, Eileen B and Fuller, Douglas S and Macfadden, Wayne and Candler, Shawn and Steininger, Teresa L and Husain, Aatif M},
title = {Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study},
journal = {Sleep Medicine},
year = {2023},
doi = {10.1016/j.sleep.2023.05.023}
}
EUVIMED